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The burden of liver disease may dramatically increase in the near
future in Africa, where screening and access to care and
treatment are hampered by inadequate disease surveillance, lack
of high-quality tools to assess chronic liver disease, and
underestimated needs for human and ﬁnancial resources. Chronic
hepatitis may be considered as silent and neglected killer, fuelled
by many years of global inertia from stakeholders and policy
makers alike. However, the global battle against viral hepatitis
is facing a new era owing to the advent of highly effective drugs,
innovative tools for screening and clinical follow-up, and recent
signs that governments, advocacy groups and global health
organizations are mobilizing to advocate universal access-
to-treatment. This review details the barriers to prevention,
screening and treatment of viral hepatitis on the African
continent, focuses on the urgent need for operational and
research programmes, and suggests integrated ways to tackle
the global epidemic.Journal of Hepatology 20
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Infection with chronic viral hepatitis affects 550 million people
worldwide compared to 33 million with HIV. In total, 350 million
are infected with hepatitis B virus (HBV), 185 million with hepa-
titis C virus (HCV) and 15 million with hepatitis delta virus [1,2].
Viral hepatitis causes substantial mortality, globally accounting
for more than 1 million deaths each year. Chronic infection is
the primary cause of hepatocellular carcinoma (HCC), which is
one of the commonest cancers in developing countries and the
third cause of cancer-related mortality worldwide [3]. The vast
majority of individuals infected with viral hepatitis live in low
to middle-income countries of Africa and Asia, where screening
and access to care and treatment are not readily available. In
Africa, about 100 million individuals are estimated to be infected
with HBV or HCV, whereas resource-rich countries account for
23 million HBV or HCV-infected subjects [4]. Because of rather
absent systematic screening policies and sub-optimal screening
practices, it is commonly reported that more than 75% of infected
individuals, living in Europe and the United States, are unaware
of their HBV and HCV status [5,6]. Even though such data are
unavailable in Africa, one might expect even higher ﬁgures con-
sidering the lack of emphasis on hepatitis screening and treat-
ment, mainly due to severely constrained ﬁnancial resources,
the unavailability and inaccessibility of tests for hepatitis virus,
as well as the insufﬁciency of well-trained health care workers.
TheWorld Health Organization (WHO) is calling for improve-
ment in interventions for the prevention, care, and control of
viral hepatitis worldwide [7–10]. With the emergence of new,
highly effective antivirals and a better implementation of HBV
vaccine campaigns, viral hepatitis eradication can be rendered
a feasible goal in Western countries [11–13]. However, a more
global vision on viral hepatitis is needed and strategies for global
eradication should be urgently extended to and implemented in
endemic resource-limited countries. This review aims at
highlighting the dramatic neglected burden of viral hepatitis in
Africa, identifying the main barriers to screening, care and15 vol. 62 j 469–476
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treatment, and suggesting global strategies that can be adapted
to the local setting.
Key Points 1
• Viral hepatitis causes substantial mortality, globally 
accounting for more than 1 million deaths each year. 
The vast majority of individuals infected with viral 
hepatitis live in low to middle-income countries of Africa 
and Asia
• Access to screening, care and treatment in Africa is 
compromised by the lack of economic and human 
resources; prevention strategies, such as the HBV 
birth dose vaccine, although recommended by the 
World Health Organization (WHO), are not implemented 
on a large scale
• There was a global, national, and international inertia 
that has started to change with the publication of WHO 
guidelines for HCV care and management in resource-
limited countries that will be shortly be followed by 
guidelines on HBV. Those are critical in shaping health 
policies at a national and regional level
• Strategies for a global approach include the 
implementation of operational and research 
programmes, the improvement of screening and 
diagnosis tools, broader access to treatment and the 
integration of prevention, screening and care for viral 
hepatitis in local health care systemsViral hepatitis in Africa: A silent and neglected killer
Burden of liver disease
In Africa, HBV and HCV infections are highly endemic and respon-
sible for 80% of cirrhosis and HCC cases, with HBV being the main
cause of end-stage liver disease [3,14,15]. HCC has been reported
as the most common cancer in males, the second commonest in
females and affects young individuals often below 40 years of
age with a rapid and fatal outcome (Fig. 1) [3]. HCV is steadily
becoming the second cause for HCC, enhanced by the widespread
exposure to aﬂatoxin, a carcinogenic mycotoxin that contami-
nates staple crops in many African countries [16]. Accurate data
in Africa on the burden of cirrhosis related to viral hepatitis are
hampered by the lack of high-quality tools to assess chronic liver
disease, inadequate disease surveillance, and poor resources for
proper data collection and management. Recent estimates show
that, with 1.4 million attributed deaths in 2010, viral hepatitis
poses a greater threat to mortality than tuberculosis or malaria
worldwide (Fig. 2) [17]. Naturally, HIV/AIDS, tuberculosis and
malaria will remain major causes of death in Africa. However, in
the case of HIV, a signiﬁcant increase in life expectancy will likely
follow after the widespread use of antiretroviral therapy (ART).
Deaths related to viral hepatitis mays subsequently increase,
concomitant to the expected decrease in AIDS-related deaths, par-
ticularly in co-infected patients, as observed in Western countries
[18,19]. As a consequence, the gain in life expectancy, as experi-
enced by HIV-infected patients, may at the end be hampered by
the burden of liver disease [20]. Other causes of liver-related470 Journal of Hepatology 201deaths, such as lifestyle-related factors (alcohol, non-fatty liver
disease) may also enhance this risk. Furthermore, the Global Bur-
den of Disease Study 2010 separated morbidity and mortality due
to cirrhosis from that of liver cancer, although both outcomesmay
be caused by chronic viral hepatitis [17]. As a result, cirrhosis and
liver cancer were ranked at number 12 and 16, respectively. Yet, if
mortality and morbidity from cirrhosis and liver cancer were
grouped together, viral hepatitis would rank within the top ten
causes of global mortality (Fig. 2), above that of tuberculosis and
malaria, which could possibly give liver diseases greater attention
to health policy makers [21].
According to WHO, HBV infection affects more than 5% of the
local population in Sub-Saharan Africa and more than 8% in West
Africa, reaching up to 15% in some areas [22]. The transmission of
the virus occurs early in life and is associated with a low rate of
spontaneous viral clearance and a high risk of chronic liver dis-
ease. It is estimated that 25% of young adults, infected during
childhood, will die prematurely from HBV-related cirrhosis or
HCC [23]. The prevalence of HCV infection varies geographically
with estimates between 3% and 5.3% [24]. However, updated epi-
demiological data on the burden of HCV infection using more
accurate methodology are missing particularly in Sub-Saharan
Africa. Egypt bears the highest prevalence worldwide with a
recent estimation of 14.7% in subjects aged 15 to 59 years [25].
This epidemic was the result of nosocomial transmission follow-
ing mass treatment of schistosomiasis with the injectable drug
antimony potassium tartrate during the 1960s. East and Central
African countries, such as Burundi, Cameroon and Gabon, are also
highly endemic for HCV with a prevalence in some areas reaching
11%, 13%, and 5% in the three respective countries [24]. In HIV-
infected individuals or other speciﬁc populations, such as drug
users, sex workers, men who have sex with men, prisoners or
patients with multiple transfusions secondary to sickle cell dis-
ease, estimates can even reach up to 50% [26,27]. The distribution
of HCV genotypes in Africa also varies by sub-regions and is
characterized by a considerable HCV subtype diversity. In West
Africa, genotypes 1, 2, and 3 are predominant, whereas in
Central Africa genotype 4 is more frequent. Genotype 5 is more
speciﬁcally observed in Southern Africa [28].Issues in prevention
HBV immunisation has been available since 1982 and has been
shown to be highly effective in reducing the prevalence of
hepatitis B surface antigen (HBsAg) in children worldwide [29].
Accordingly, national immunisation programmes have led to a
substantial decrease in the burden of chronic liver disease and
HCC in young adults born after 1984 [30,31]. With the support
of WHO and the Global Alliance for Vaccine and Immunization
(GAVI), most African countries have elected to vaccinate all
children against HBV through the WHO-sponsored expanded
programme of immunisation. However, HBV vaccine coverage
remains low or incomplete (around 79% of vaccine coverage for
Africa as a whole [32]). Furthermore, current recommendations
from WHO-AFRO state that birth dose HBV vaccination should
be given to prevent maternal-to-child vertical transmission and
early horizontal transmission, yet its implementation has been
lacking thus far [33]. This issue is critical, as over 90% of children
infected with HBV early in life will become chronic carriers of the
virus, adding to their risk of cirrhosis and HCC. WHO estimates
that very few countries have implemented an HBV birth dose5 vol. 62 j 469–476
Fig. 1Incidence of HCC worldwide in both sexes (GLOBOCAN, 2012). From Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M.,
Forman D., Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on
Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 24/11/2014.
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Fig. 2. Number of deaths attributable in 2010 to HIV/AIDS, viral hepatitis,
malaria and tuberculosis (adapted from Lozano et al. [17]).
JOURNAL OF HEPATOLOGYvaccine strategy and that only 23% of children born in the African
continent beneﬁt from the early birth dose. Even in the Gambia,
one of the ﬁrst countries to have implemented an HBV immuni-
sation national programme in 1984 through the Gambian
Hepatitis Intervention Study (GHIS), birth dose within the ﬁrst
24 h of life is given to less than 3% of new-borns [34]. HBV
mother-to-child transmission may also occur in 2–30% of infants
born to HBV-infected mothers, while several African studies have
shown that mother-to-child transmission is reduced, but still
occurring in 2–10% of hepatitis B envelope antigen (HBeAg)-
negative mothers with low viral loads [35]. Despite these alarm-
ing ﬁgures, only three countries (Cameroon, Mauritania and
Rwanda) have established national guidelines on HBV mother-
to-child transmission. In addition, pregnant women in Africa
are not systematically screened for chronic HBV infection or
suitably informed about HBV infection.Journal of Hepatology 201Nosocomial transmission is another major route of viral
hepatitis transmission in Africa. WHO estimates that 24% of blood
donations in low-income countries are not systematically
screened for HBV/HCV and 2 million new HCV infections world-
wide result from unsafe injections each year. The lack of efﬁcient
HBV and HCV screening in blood banks is now mainly a conse-
quence of blood donated within the window period during which
standard tests cannot detect viral infection. Nucleic acid detection
may increase the chance of detecting an ongoing acute viral infec-
tion but at a price of increased screening costs. In 2000, about 20%
of medical injections were estimated to be administrated under
unsafe conditions [36]. Transmission of HCV through medical or
dental procedures has also been documented in many African
countries. The prime illustration of such transmission is Egypt
with the national campaign to eradicate schistosomiasis using
reusable syringes. Other campaigns like these have led to the rapid
spread of HCV, as noted for treatment programmes against
malaria in Cameroon [37] and Gabon [38]. In addition, a case-
control study in Egypt revealed a signiﬁcantly higher odds of
recent attendance at medical or dental facilities in subjects with
acute HCV infection [39]. These routes of transmission pose
serious concern, as further transmission can occur within
households [40].
It should be mentioned that injecting drug use has recently
emerged as a concern for HCV transmission in Africa, despite that
fact that it is not the main mode of transmission. Silent and hid-
den epidemics of HCV have been identiﬁed among intravenous
drug user from several Sub-Saharan African capitals, such as
Dakar or Dar-Es Salam [41,42]. More well-deﬁned and appropri-
ate identiﬁcation of HCV transmission routes in Sub-Saharan
Africa is needed.
Halting transmission of HBV and HCV requires in part effective
treatment of chronically infected subjects. However, there is a5 vol. 62 j 469–476 471
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variety of issues in Africa that matches the recent advances
achieved in therapeutic efﬁcacy. First, in order to have a higher
impact on liver-related mortality and public health, higher
emphasis on HCV screening must be given in conjunction with
highly-effective treatment [43]. Second, one oftentimes
overlooked aspect of treatment is the need for liver-oriented care,
which remains a challenge for much of Africa. The number of
trainedmedical doctors and nurses in hepatology is limited, while
at the same time laboratory prognostic indicators (e.g. viral load
quantiﬁcation, genotyping) are expensive and not always feasible
in routine. Assessing liver ﬁbrosis is often difﬁcult. Liver biopsies
are invasive and costly and require trained histopathologists who
are not common in Africa. Non-invasivemarkers can be used as an
alternative (Fibroscan, FibroTest, FibroMeter), yet are still
expensive and involve quantiﬁcation of several biochemical
parameters that are not customarily available in local laborato-
ries. There are other non-invasive ﬁbrosis tests, based on a combi-
nation of simple and cheap markers (AST, ALT, platelets, and age),
such as APRI and FIB4. However, their diagnostic performance
needs to be more precisely deﬁned in resource-limited settings
before warranting extended use [44,45]. Finally, reduced access
to potent drugs in Africa allows only a minority of patients to be
treated for HBV or HCV. Of course, the exception is Egypt, where
50,000 HCV-infected patients have been treated through efforts
from both the government and medical community, committed
towards providing access to low-priced generic antivirals.
However, it is estimated that 250,000 infected subjects per
year should be effectively treated if the aim is to reduce
HCV-prevalence below 2% [46].
Political, national, and international inertia
It can be argued that the burden of disease generated by viral hep-
atitis has been completely ignored by the international health
agenda over the past few decades. Indeed, part of this could be
due to the silent and chronic nature of HBV or HCV infections,
which, compared to diseases like HIV, tuberculosis, and malaria;
do not progress as quickly, do not possess the same frequency
of visible trauma, and are maybe less stigmatizing. The result
has been a galvanization of political and public actors to act
against HIV, tuberculosis, and malaria – diseases that have
received the bulk of health care resources and funding. Yet, as
discussed earlier, the burden of viral hepatitis needs to be seri-
ously reconsidered by international health authorities, especially
when accounting for the overall morbidity and mortality of both
cirrhosis and liver cancer [21].
Only until recently hasWHO expressed any strong interest to
ﬁght the burden of viral hepatitis, with the ﬁrst resolution on
viral hepatitis adopted in July 2010 [7] and a second one voted
inMay 2014 (WHA 67.6). WHO guidelines for the screening, care
and treatment of HCV have been developed and published very
recently [47]. To date, no WHO guidelines of this nature are
available for HBV, although they are currently underway with
plans to be released by the beginning of 2015 at the latest. These
international guidelines are critical in shaping health policies at
the national level and helping governments to support access to
screening and treatment for viral hepatitis in the future. Cur-
rently, very few developing countries have established national
strategies on viral hepatitis infection and, when available,
guidelines are often incomplete (i.e. lack of screening strategies,
no mention of liver disease evaluation and care for advanced472 Journal of Hepatology 201liver disease). In Africa alone, only 17 countries have adopted
local guidelines, which mainly address issues in prevention.
Likewise, funding for chronic viral hepatitis has been by no
means signiﬁcant in Africa, where national public health expenses
and health expenses per habitant are very low. Despite the impor-
tance of liver disease attributable to viral hepatitis infections,
major contributors to global health development, such as the Uni-
ted Kingdom Department for International Development and the
Bill and Melinda Gates Foundation do not prioritize viral hepatitis
research or programme development. Research agencies, such as
the ANRS (French Research Agency on HIV/AIDS and viral hepati-
tis) in France and the GTZ/GIZ (Deutsche Gesellschaft für Techni-
sche Zusammenarbeit/Deutsche Gesellschaft für Internationale
Zusammenarbeit) in Germany have invested in African research
programmes on viral hepatitis, but the ongoing research there
has yet to have an impact on health policies. The Global Fund
and PEPFAR (United States President’s Emergency Plan for AIDS
Relief), who provide ﬁnancing for the treatment of HIV, tuberculo-
sis, and malaria, have only until recently been able to provide
funds for the ﬁght against viral hepatitis in Africa. It should be
noted that other stakeholders, such as UNITAID, have announced
future funding for Hepatitis C care and prevention [48], but they
will most likely need other operational resources, such as non-
governmental agencies (Médecins Sans Frontières, www.msf.org;
Médecins du Monde, www.medecinsdumonde.org) or bilateral
cooperations (e.g. ESTHER, www.esther.fr), in order to more
ﬂuidly implement their programmes.Barriers to screening, care, and treatment
Screening
Detecting cases of viral hepatitis is a necessary step in reducing
transmission, but also pivotal in identifying those who need
access to treatment. Unfortunately, screening remains expensive
and its quality is insufﬁcient for much of Africa, where the vast
majority of patients are unaware of their diagnosis. To date, it
is estimated that up to 90% of HCV-infected individuals
worldwide do not know that they are HCV-positive [49]. In The
Gambia, the PROLIFICA (Prevention of Liver Fibrosis and Cancer
in Africa) programme (http://proliﬁca.eu/activity/2012/recruit-
ing-known-hbv-carriers-in-rural-gambia/) found that less than
1% of adults who tested positive for HBsAg at the community
level had been previously tested and were aware of their diagno-
sis (personal data). This lack of awareness could be partially
accounted for by the many barriers to screening. For instance,
access to high-quality laboratories are oftentimes conﬁned to
urban areas, with rural and remote populations having almost
no access. Irregular supply of test kits is another common prob-
lem faced by many clinical facilities. Therefore, it comes as no
surprise that nearly two-thirds of the world population live in
countries where viral hepatitis testing is not accessible, according
to 2010 data from the World Hepatitis Alliance/WHO [29].
Care and treatment
In terms of providing care, one major barrier is the absence of
reliable, simple and cheap viral load assays. Virological tests
(serology, viral load quantiﬁcation, genotyping) are still very
expensive (€70 to €150 for HBV or HCV PCR) and are typically5 vol. 62 j 469–476
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supported ﬁnancially by the patients themselves whose daily
income is less than €2. As mentioned above, easy and cheap
screening tools for assessing liver disease severity are also sorely
lacking. As a result, liver disease is commonly diagnosed when
severe, late-stage symptoms appear. The limited access of these
expensive tools will be a major impediment to extended
programmes for viral hepatitis.
Viral eradication or control of viral replication has been dem-
onstrated to signiﬁcantly decrease the risk of cirrhosis and its
complications, including HCC [50–52]; while even demonstrating
signs of ﬁbrosis and cirrhosis regression [53]. Of certain, viral
control is most efﬁciently achieved with antiviral therapy. HBV
treatment has been greatly improved by second generation,
potent nucleos(t)ide analogues (tenofovir, entecavir), whereas
HCV treatment is currently facing a major shift in the treatment
paradigm, with short, well tolerated and highly effective regi-
mens. However, programmes evaluating treatment effectiveness
on viral hepatitis are currently sparse in sub-Saharan Africa. The
research programme PROLIFICA, presented above, also aims at
determining the long-term impact of tenofovir disoproxil fuma-
rate (TDF) on liver cancer incidence among HBV-monoinfected
patients. Such programmes, evaluating hepatitis C treatment
based on the new direct-acting antiviral agents, are presently
lacking. A pilot project, assessing the feasibility of interferon-free
therapy in Sub-Saharan Africa using sofosbuvir-ribavirin in
combination, may start in October 2014 with the support of ANRS
and Gilead Sciences.
Cost of the drugs
Unfortunately, drug cost is one of the main barriers for access to
treatment in Africa. According to a collaborative study between
the World Hepatitis Alliance and WHO, 41% of the world’s
population live in countries where no public funding is available
for viral hepatitis B/C treatment, with a particular gap in access to
anti-HCV treatments [29].
Restricted access to anti-HBV treatment continues to be a
problem for patients with chronic hepatitis in Africa. The price
of generic TDF has been negotiated to as low as €26 per year of
treatment [54], which has been made possible mainly from funds
by the Global Fund and PEPFAR. Since these treatments are only
available to HIV-infected patients, non-HIV-infected patients are
paradoxically discriminated against. HBV-monoinfected patients
consequently receive antivirals with less potency, namely
lamivudine, as ﬁrst line treatments against hepatitis B, posing a
major concern for drug resistance and higher risk of liver-related
mortality [52].
Because African countries cannot afford the high costs of anti-
HCVdrugs, any access to treatment campaignwould be contingent
on the availability of less expensive options. A 48-week course of
pegylated-interferon/ribavirin treatment still costs approximately
€15,000 to €25,000,without taking into account the additional lab-
oratory and medical costs. First generation direct-acting antiviral
agents (DAAs) are more expensive (€20,000–40,000 per year for
telaprevir or boceprevir) and are probably not adapted to
resource-limited settings. Prices of second-generation DAAs are
expected to be even higher. For example, sofosbuvir (Gilead,
USA), providing high sustained virological response (SVR) rates
with or without concomitant interferon, has been recently
licensed in the United States and Europe at US $70,000 or
€66,000 for a 12-week course of treatment (i.e. US $1000 orJournal of Hepatology 201€700/pill). Other interferon-free regimens have provided SVR rates
reaching almost 100% in both HCV and HIV/HCV-infected patients,
but are also expected to be extremely expensive, questioning their
uptake even for high-resource countries [55]. To date, only Egypt
and India have succeeded in negotiating reduced prices of
sofosbuvir. Indeed Egypt has a long-term commitment to HCV
treatment, as evidence by their previous involvement with
Peg-interferon/RBV [56]. Other resource-limited countries have
initiated discussions around access to low-priced sofosbuvir, but
no agreements have been signed thus far. Access to treatment
for all might also be limited by time constrains, associated with
registering speciﬁc treatments to theWHOEssentialMedicine List,
after which countries may be able to negotiate prices with phar-
maceutical companies or generic-producing ﬁrms.Strategies for a global approach
Need for operational and research programmes
As stated in a recent editorial appearing in the Lancet [11], ‘‘The
need for a global plan for hepatitis C is imperative. It should
include research and operational priorities, and establish global
fundingmechanisms. Countries are only likely to develop national
plans for hepatitis C when treatments become more affordable.’’
Research and operational projects on HBV are very scarce in
Sub-Saharan Africa. Increasing knowledge on global HCV/HBV
prevalence and risk factors for transmission should be a priority
through well-deﬁned epidemiological surveys, as to prevent
biases arising from studies done in small targeted groups. Popula-
tion-based screening programmes are indeed decisive for
resource-limited settings in evaluating effective cost-effective
approaches combining screening and treatment strategies. The
PROLIFICA programme in The Gambia and Senegal is one of the
few addressing the issue of HBV testing, combined to the severity
assessment of chronic hepatitis B and to the screening of liver
cancer. It also aims at demonstrating the efﬁcacy of TDF-based
antiviral therapy for preventing cirrhosis and HCC in West Africa.
Other operational programmes, such as the integrated one from
Egypt [46] have a provided cost-effectiveness analysis that has
been instrumental in adapting local strategies against viral
hepatitis infection.
Improving screening and diagnosis
A number of innovative diagnostic tools have been recently
developed that could signiﬁcantly improve screening and liver
assessment at a low cost. Point-of care (POC) tests for HBsAg
and HCV antibodies are now available for facilitated use at the
community level, in particular, rural populations living in difﬁ-
cult-to-reach or remote areas. Their performance has been vali-
dated in both Europe and Sub-Saharan Africa. In The Gambia,
good sensitivity and speciﬁcity of two HBsAg POC tests have been
observed [57], similar to another large study conducted in France
[58]. However, some HCV POC tests (e.g. OraQuick) are still
expensive, with some concern regarding their performance in
HIV-HCV co-infected individuals [59].
New techniques of viral detection have also been validated
on dry blood spots, which could help evaluate treatment
response and could assist in screening for actively infected
individuals [60–62]. Some companies are developing POC5 vol. 62 j 469–476 473
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devices to quickly quantify viral load at a lower cost while
adapted to the local African environment. HCV core antigen is
another compelling alternative method that could be used as a
non-expensive proxy for HCV-RNA viral loads. This tool has been
mainly analysed in developed countries [63,64], yet could be eas-
ily adapted for HCV screening in Africa [65]. Taken together, it is
hoped that these innovative diagnostic tools could improve access
to screening, care and treatment in the near future.
Broadening access to treatment
Broadening access to treatment for viral hepatitis in Africa
urgently requires: (1) access to diagnostic strategies and drugs
at low prices, (2) involvement and subsidies from local govern-
ments, (3) support from pharmaceutical companies and interna-
tional health agencies intending to establish public-private
partnerships that include patient advocacy groups, and (4) oper-
ational and research programmes to properly assess the local
needs and demonstrate the cost-effectiveness of screening and
therapeutic interventions.
Alternative solutions to overcome the barriers of cost do exist
andnegotiations betweenpolicymakers and pharmaceutical com-
panies have commenced. The experiences from Egypt and India
have taught stakeholders that it is entirely possible to obtain anti-
viral drugs at lowprices. Since 1995, drugproductionhas been reg-
ulated by the agreements of Trade-Related Aspects of Intellectual
Property Rights, instituted by the World Trade Organization [66].
These agreements mean that all countries, regardless of available
resources, must complywith a 20-year patent protection for phar-
maceutical products in order to remain members of the World
Trade Organization and to be able to access the global market.
Consequently, countries cannot produce generic versions of a
treatment until 20 years after its release, conferring a strong
monopoly to the drug’s patent holder, while the drug’s price is
determined by the highest the market can bear. This greatly limits
the affordability and availability ofmanydrugs, including essential
medications, leading tomillions of avoidable deaths. However, the
Doha declaration on Trade-RelatedAspects of Intellectual Property
Rights and public health allows compulsory licenses for selected
medicines ‘‘to protect public health and promote access to medicines
for all’’ [67]. In response, countries like India or Brazil have been
able to produce generic drugs still under patent protection. For
example, ever since the Indian Government declared liver cancer
a public health issue, sorafenib, the only oral chemotherapy
against HCC, was produced in India, resulting in price decreases
of 60% at €150/month (Soranib, Cipla). Gilead company has also
recently signed non-exclusive licensing agreements with seven
India-based generic pharmaceutical manufacturers to produce
sofosbuvir at generic price. Least but not last, broadening access
to treatment also means offering treatment to the most difﬁcult
to reach infected population, such as intravenous drug users
(IVDU). Written along with the Hepatitis Coalition (www.hepco-
alition.org), The Médecins du Monde position paper ‘‘Nobody left
behind’’ is indeed recalling why treatment access integrated to
substitution programmes should be privileged [68]. Research pro-
grammes focused on IVDU, such as the ACTIVATE programme
(http://www.kirby.unsw.edu.au/projects/activate-collaborative-
trial-injectors-individualized-treatment-genotype-23) are also
essential in documenting tolerance, efﬁcacy and feasibility of
HCV treatment based on DAAs and will help advocating for access
to HCV treatment for all.474 Journal of Hepatology 201Integrating screening and care for viral hepatitis in the local health
care system
From lessons of the HIV/AIDS epidemic, the same energy and
mobilization must be applied to ﬁght viral hepatitis [69]. Until
the mid-2000s, ART was costing more than $10,000 per patient
per year and was not considered cost-effective [70]. Today, fol-
lowing strong pressure on policy-makers and pharmaceutical
companies by patient advocacy groups, cost has fallen to less
than $100 per person per year. Subsequently, the number of
individuals receiving ART in developing countries has consider-
ably increased from 200,000 in 2000 to 10 million today, repre-
senting 0.1% in 2000 to 61% in 2012 of African individuals with
HIV receiving ART (according to the 2010 WHO ART guidelines,
the percentage may be lower when the 2013 WHO ART guide-
lines, recommending ART-introduction at a higher CD4 T cell
level of 500/mm3, will be largely applied) [71]. This example
must be applied to the viral hepatitis epidemic.
Furthermore, viral hepatitis should be integrated in the local
health care systems in Africa. Streamlining screening, care and
treatment of viral hepatitis within concurrent HIV/AIDS, tubercu-
losis or malaria programmes could be a solution, especially con-
sidering that a global fund for viral hepatitis is unlikely to be
created in the near future. Incidentally, public health policy mak-
ers are now becoming more willing to develop and reinforce hor-
izontal approaches of health programs. Thus, the feasibility and
evaluation of such approaches is vital in providing care to persons
infected with viral hepatitis.Conclusion
The advent of innovative diagnostic tools and highly effective
antiviral drugs has brought way to a new era in the care and treat-
ment of viral hepatitis. From a global health perspective, it has
become urgent to incorporate these advances in resource-limited
countries, where the worldwide endemic of viral hepatitis is
concentrated. In Africa, the burden of viral hepatitis requires
immediate strategies to improve prevention, screening, care and
treatment; which might be achieved through existing health care
infrastructure. Operational programs and clinical trials should be
conducted in Africa with the support of local governments and the
international health community. The recent call for action by
WHO, through the Global Hepatitis Programme and Global Part-
ners needs indeed to be translated into concrete action [72].Financial support
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